Relieves bronchospasm. ANDA 75664, held by Nephron. Albuterol Sulfate.
As of Nov 16, 2026, ANDA 75664 (Albuterol Sulfate), held by Nephron, was first approved by FDA on Jun 26, 2001, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol inhalation solution is indicated for the relief of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 26, 2001 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Albuterol SulfateEQ 0.5% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| Mar 29, 2007 | Supplement 2Labeling | Approved | None posted |
| Jun 26, 2001 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters